Simple Summary The clinical management of bladder cancer has been develo** in the
past decade, including diagnostic tools and treatment options. Both monotherapy and …

Introduction Failure, intolerance, or shortage of bacillus Calmette-Guerin (BCG) treatment for
patients with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) leave many facing …

Introduction Intravesical gemcitabine and docetaxel (Gem/Doce) has been established as a
safe and efficacious salvage treatment for recurrent NMIBC since 2015. Despite widespread …

Purpose This study reports the safety and efficacy of Oncofid− PB, a novel compound under
development by Fidia Farmaceutici SpA with specific binding to CD44 receptor, in patients …

The current landscape of salvage therapies for patients with... : Current Opinion in Urology The
current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive …

Background Bladder cancer (BC) is the most common malignant tumor of the urinary system.
Gemcitabine resistance partly accounts for treatment failure and recurrence in BC …

Background and objective Non–muscle-invasive bladder cancer (NMIBC) poses a
significant clinical challenge, particularly when failing bacillus Calmette-Guérin (BCG) …

Simple Summary The mainstay of treatment for non-muscle invasive bladder cancer is
transurethral resection of the tumor followed by intravesical treatment for intermediate-or …

Non-muscle invasive bladder cancer is a common tumour in men and women. In case of
resistance to the standard therapeutic agents, gemcitabine can be used as off-label …

Background Non-muscle invasive bladder cancer (NMIBC) represents the majority of
bladder neoplasms. It is unusual for NMIBC metastasizing distantly without regional …